Zacks: Analysts Set $46.25 Target Price for Menlo Therapeutics (MNLO)

Shares of Menlo Therapeutics (NASDAQ:MNLO) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price target of $46.25 for the company and are expecting that the company will post ($0.68) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Menlo Therapeutics an industry rank of 183 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

MNLO has been the subject of a number of research reports. JMP Securities initiated coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set an “outperform” rating and a $44.00 target price for the company. Guggenheim initiated coverage on Menlo Therapeutics in a report on Monday, February 19th. They set a “buy” rating and a $52.00 target price for the company. Jefferies Group initiated coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set a “buy” rating and a $41.00 target price for the company. Finally, Piper Jaffray initiated coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set an “overweight” rating and a $48.00 target price for the company.

In other news, major shareholder Vivo Capital Surplus Fund Viii bought 294,118 shares of the firm’s stock in a transaction that occurred on Thursday, January 25th. The stock was purchased at an average price of $17.00 per share, with a total value of $5,000,006.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Menlo Therapeutics stock opened at $35.22 on Friday. Menlo Therapeutics has a 52 week low of $20.50 and a 52 week high of $39.86. The stock has a market cap of $809.29 and a P/E ratio of -6.19.

Menlo Therapeutics (NASDAQ:MNLO) last released its earnings results on Wednesday, March 28th. The company reported ($1.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($1.11). The company had revenue of $2.78 million during the quarter. analysts expect that Menlo Therapeutics will post -3.19 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Set $46.25 Target Price for Menlo Therapeutics (MNLO)” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3340495/zacks-analysts-set-46-25-target-price-for-menlo-therapeutics-mnlo.html.

About Menlo Therapeutics

Menlo Therapeutics Inc, a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Investors Sell Shares of iShares S&P 500 Value ETF  on Strength
Investors Sell Shares of iShares S&P 500 Value ETF on Strength
Investors Buy Analog Devices  on Weakness
Investors Buy Analog Devices on Weakness
WETH Trading Up 28.3% Over Last Week
WETH Trading Up 28.3% Over Last Week
Incent  Market Capitalization Hits $18.58 Million
Incent Market Capitalization Hits $18.58 Million
Analyzing Apple  & Omnicell Technologies
Analyzing Apple & Omnicell Technologies
Investors Buy Vanguard FTSE All-World ex-US ETF  on Weakness
Investors Buy Vanguard FTSE All-World ex-US ETF on Weakness


© 2006-2018 Ticker Report. Google+.